FibroGen Reports Second Quarter 2019 Financial Results
FibroGen, Inc (FGEN)
Last fibrogen, inc earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=253783&p=irol-irhome
Company Research
Source: GlobeNewswire
— On Track to Submit U.S. NDA for Roxadustat in October —— Initiated ZEPHYRUS Phase 3 Study of Pamrevlumab in IPF — Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter of 2019 and provided an update on the company’s recent developments. “This has been a very productive quarter with the achievement of multiple regulatory and clinical milestones. We had a positive pre-NDA meeting with the FDA on roxadustat. Supported by positive efficacy and safety data, including compelling MACE and MACE+ results, we look forward to submitting our U.S. NDA in October. In IPF, the first patient was dosed in our Phase 3 pamrevlumab program,” said Thomas B. Neff, Chief Executive Officer. “We are pleased to see the publication of two articles in the New England Journal of Medicine on our pivotal roxadustat Phase 3 studies in China.” Recent Developme
Show less
Read more
Impact Snapshot
Event Time:
FGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FGEN alerts
High impacting FibroGen, Inc news events
Weekly update
A roundup of the hottest topics
FGEN
News
- Global Duchenne Muscular Dystrophy Drugs Market Set to Reach $ 5.5 Billion by 2032, With a CAGR of 10.17% Driven by New Product Approvals, Launches, and a Favorable Landscape [Yahoo! Finance]Yahoo! Finance
- FibroGen to Report First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- FibroGen to Report First Quarter 2024 Financial ResultsGlobeNewswire
- FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology AAcquire Media Monitor
- FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology GlobeNewswire
FGEN
Earnings
- 2/26/24 - Miss
FGEN
Sec Filings
- 4/25/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- FGEN's page on the SEC website